AAP
VRCA icon

Arax Advisory Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

Arax Advisory Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9
Closed -$38 – 4556
2025
Q3 		$38 Buy
+9
New +$54 ﹤0.01% 3547
2024
Q4 		– Sell
-24
Closed -$350 – 2766
2024
Q3 		$350 Hold
24
– – ﹤0.01% 2453
2024
Q2 		$1.76K Buy
+24
New +$1.84K ﹤0.01% 2015

Other funds holding VRCA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arax Advisory Partners's VRCA Position: Q4 2025 in Review

Arax Advisory Partners sold out of Verrica Pharmaceuticals (VRCA) in Q4 2025, closing a stake of 9 shares — an estimated $38 sold.

Arax Advisory Partners first reported a position in VRCA in Q2 2024 and held it in 3 quarters. The position peaked at $1.76K in Q2 2024. 50 funds tracked by Wall St. Rank hold VRCA as of Q4 2025.

  • Arax Advisory Partners reported no remaining Verrica Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 9 Verrica Pharmaceuticals shares in Q4 2025, an estimated $38.
  • Arax Advisory Partners first reported a position in Verrica Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Arax Advisory Partners's Verrica Pharmaceuticals position peaked at $1.76K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.